Fortney Kristen 4
4 · BioAge Labs, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
BioAge (BIOA) CEO Kristen Fortney Receives 330,000-Share Award
What Happened
- Kristen Fortney, Chief Executive Officer of BioAge Labs, Inc. (BIOA), received a derivative award of 330,000 shares on February 17, 2026. The filing lists the acquisition price as $0.00 (transaction code A — grant/award). This is a compensation grant, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-17; Filing date (accession): 2026-02-19 (filed within the normal two-business-day Form 4 window).
- Shares/units granted: 330,000 (derivative award); reported acquisition price: $0.00.
- Shares owned after the transaction: not specified in the excerpt provided.
- Footnote: The award vests 1/48th monthly, with the first tranche having vested on February 1, 2026; subsequent tranches vest on each monthly anniversary, subject to continued service.
- No sale, cashless exercise, tax-withholding, or 10b5-1 plan noted in the reported transaction.
Context
- This is a typical executive compensation grant (derivative award) that vests over four years on a monthly schedule. Such grants are common and do not by themselves indicate an immediate buy or sell signal; they reflect ongoing compensation and retention incentives.
Insider Transaction Report
Form 4
Fortney Kristen
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-02-17+330,000→ 330,000 totalExercise: $19.63Exp: 2036-02-16→ Common Stock (330,000 underlying)
Footnotes (1)
- [F1]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Signature
/s/ Dov A. Goldstein as attorney-in-fact|2026-02-19